MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research to evaluate multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Main demo goals ended up To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis patients, while one of many exploratory https://su951643219.ssnblog.com/30211128/considerations-to-know-about-sifalimumab